Clinical Trial Update: A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating multiple doses of BI 1823911 alone and in combination for various advanced cancers with KRAS mutations; the study status is ACTIVE_NOT_…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kras-mutant Solid Tumors

Drugs mentioned

• BI 1823911

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Solid Tumors, KRAS Mutation | Phase 1 | Status: ACTIVE_NOT_RECRUITING